Back to results
US 2012/0231027 A1Published application
Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsEric VAUGHN, Paulino Carlos GONZALEZ-HERNANDEZ, Juergen DAEMMGEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
Claims19
A vaccine comprising
- a. one or more immunogenic components selected from the group consisting of
- i. an isolated nucleic acid encoding a recombinant H5 protein, wherein the recombinant H5 protein comprises SEQ ID NO:
- 4 and includes amino acid 223N, modification 328K+, and amino acid 94N, wherein numbering of the amino acid positions refers to the amino acid position as exemplified by SEQ ID NO:
- 1 and wherein the modification 328K+ means that a second lysine (K+) is inserted at amino acid position 328 of the H5 protein,
- ii. a vector comprising the isolated nucleic acid,
- iii. the recombinant H5 protein, and
- iv. any combination thereof;
- and
- b. a pharmaceutical acceptable carrier and/or excipient.
6 more elements
A method of making a vaccine comprising:
- a. obtaining one or more immunogenic components selected from the group consisting of
- i. an isolated nucleic acid encoding a recombinant H5 protein, wherein the recombinant H5 protein comprises SEQ ID NO:
- 4 and includes amino acid 223N, modification 328K+, and amino acid 94N, wherein numbering of the amino acid positions refers to the amino acid position as exemplified by SEQ ID NO:
- 1 and wherein the modification 328K+ means that a second lysine (K+) is inserted at amino acid position 328 of the H5 protein,
- ii. a vector comprising the isolated nucleic acid,
- iii. the recombinant H5 protein, and
- iv. any combination thereof;
- and
- b. admixing one or more immunogenic components with a pharmaceutical acceptable carrier and/or excipient.
6 more elements
Dependencies are inferred from the claim text.